Home / Recalls / Tailstorm Health INC / D-0051-2025

D-0051-2025 Class II Terminated

Recalled by Tailstorm Health INC — Phoenix, AZ

Recall Details

Product Type
Drugs
Report Date
November 27, 2024
Initiation Date
November 6, 2024
Termination Date
March 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
27,560 Syringes

Product Description

BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syringe, Rx Only, Repackaged by: Medivant Healthcare: 24416 N 19th Ave, Phoenix, AZ, NDC 81483-0041-1

Reason for Recall

Lack of Sterility Assurance

Distribution Pattern

Nationwide Within U.S.

Code Information

Lot #: D24005, Exp. Date 20 February 2025; D24006, Exp. Date 21 February 2025; D24007, Exp. Date 22 February 2025; D24008, Exp. Date 19 March 2025; D24009, Exp. Date 20 March 2025; D24012, Exp. Date 25 April 2025.

Other recalls by Tailstorm Health INC

  • D-0502-2025 Class II — LIDOcaine HCL Sterile Injection, USP, 100mg/10mL, 1%, (10mg/mL), w/EPINEPHRINE 1 (June 2, 2025)
  • D-0499-2025 Class II — BUPIVAcaine HCL Sterile injection, USP w/EPINEPHRINE 1:200,000, 50 mg/10mL, 0.5% (June 2, 2025)
  • D-0501-2025 Class II — KETAmine Hydrochloride Injection, USP, 500mg/5mL, (10mg/mL), For IM or Slow IV U (June 2, 2025)
  • D-0503-2025 Class II — LIDOcaine HCL Sterile Injection, USP, 20 mg/mL, 2%, (200 mg/10 mL), For Infiltra (June 2, 2025)
  • D-0498-2025 Class II — LIDOcaine HCl Injection, USP, 10mg/mL, 1% (100 mg/10mL), 10 mL Sterile Single Do (June 2, 2025)
  • D-0500-2025 Class II — KETAmine Hydrochloride Injection, USP, 50 mg/5mL (10 mg/mL), For IM Use or Slow (June 2, 2025)
  • D-0594-2024 Class II — Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:200,0 (July 3, 2024)